Imunon

Imunon FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Imunon (IMNN) as of Oct 15, 2026 is 97.81 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 101.42 % — a change of -3.56% (lower).

FCF Conversion

97.81 %

YoY

-3.56%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Imunon is 2025 97.81 % . FCF Conversion Rate (FCF/EBITDA) of Imunon was 2024 101.42 % . It decreases by -3.56% lower compared to the previous year.

The Imunon FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
60.42 USD
Jan 1, 2019
122.29 USD
Jan 1, 2020
72.79 USD
Jan 1, 2021
79.61 USD
Jan 1, 2022
65.09 USD
Jan 1, 2023
99.79 USD
Jan 1, 2024
101.42 USD
Jan 1, 2025
97.81 USD
The Imunon FCF Conversion history
YEARFCF ConversionYoY
97.81 %-3.56%
101.42 %+1.63%
99.79 %+53.32%
65.09 %-18.25%
79.61 %+9.38%
72.79 %-40.48%
122.29 %+102.40%
60.42 %-26.10%
81.76 %-2.23%
83.62 %-10.30%
93.23 %+7.91%
86.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imunon Stock analysis

What does Imunon do? Imunon Inc is a clinical stage oncology drug company headquartered in Lawrenceville, New Jersey. The company has 31 full-time employees and went public on October 27, 1993. Imunon focuses on developing treatments that leverage the body's natural mechanisms for various diseases. It operates two platform technologies: the TheraPlas platform for immunotherapies and nucleic acid-based anti-cancer therapies, and the PLACCINE platform for nucleic acid vaccines targeting infectious diseases and cancer. The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy designed for localized treatment of advanced ovarian cancer. IMNN-001 functions by prompting the body to generate cancer-fighting molecules like interleukin-12 and interferon gamma directly at the tumor site. Additionally, Imunon is conducting preclinical research on a nucleic acid vaccine candidate against the SARS-CoV-2 virus to validate its PLACCINE platform. The company's technologies rely on synthetic delivery systems for nucleic acids, avoiding viral vectors or devices. Imunon's website is https://imunon.com/ and it is listed under the ticker IMNN with ISIN US15117N7012. The company operates within the health care sector, specifically in biotechnology. Imunon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imunon stock

FCF Conversion Rate (FCF/EBITDA) of Imunon is 97.81 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Imunon changed from 101.42 % to 97.81 %, representing a -3.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Imunon since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Imunon with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Imunon

All Key Metrics — Imunon